E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients with fecal incontinence who have failed conservative treatments and are candidates for intrarectal botulinum toxin injections. |
Patients souffrant d’incontinence fécale en échec des traitements conservateurs et candidats aux injections intra-rectales de toxine botulique. |
|
E.1.1.1 | Medical condition in easily understood language |
Patients with fecal incontinence |
Patients souffrant d’incontinence fécale |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Digestive System Diseases [C06] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10016296 |
E.1.2 | Term | Fecal incontinence |
E.1.2 | System Organ Class | 100000004856 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To study, 1 month after intra-rectal injections, the effect of botulinum toxin on rectal motricity stimulated by laxative instillation and recorded in high resolution manometry. |
Étudier, 1 mois après la réalisation des injections intra-rectales, l’effet de la toxine botulique sur la motricité rectale stimulée par l’instillation de laxatifs et enregistrée en manométrie haute-résolution. |
|
E.2.2 | Secondary objectives of the trial |
- Evaluate the clinical efficacy of botulinum toxin injections at 1 month after injections. - Evaluate the quality of life at 1 month after the injections - Evaluate the tolerance of botulinum toxin injections |
- Évaluer l’efficacité clinique des injections de toxine botulique à 1 mois des injections. - Évaluer la qualité de vie à 1 mois des injections - Évaluer la tolérance des injections de toxine botulique |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Active or predominantly active fecal incontinence with failure of first-line conservative treatments (normalization of transit, perineal rehabilitation) - Impairment of quality of life left to the discretion of the investigator - Patients at least 18 years old - Patients who have read and understood the information letter and signed the consent form - Patients affiliated to the French Social Security system - Women of childbearing age with effective contraception (Cf. CTFG) (estrogen-progestin or intrauterine device or tubal ligation) and a negative urine pregnancy test by -HCG at inclusion, during the study period. - Postmenopausal woman: confirmatory diagnosis (non-medically induced amenorrhea for at least 12 months prior to the inclusion visit) - Men with a partner of childbearing age who must take contraception (Cf. CTFG) (estrogen-progestin or intrauterine device or tubal ligation) at inclusion, for the duration of the study. |
• Incontinence fécale active ou à prédominance active avec échec des traitements conservateurs de 1ère intention (normalisation du transit, rééducation périnéale) • Altération de la qualité de vie laissée selon l’appréciation de l’investigateur • Patients âgés d’au moins 18 ans • Patients ayant lu et compris la lettre d’information et signé le consentement • Patients affiliés au régime de la Sécurité Sociale • Femme en âge de procréer ayant une contraception efficace (Cf. CTFG) (oestro-progestatifs ou dispositif intra-utérin ou ligature de trompes) et un test de grossesse urinaire par -HCG négatif à l’inclusion, pendant la durée de l’étude. • Femme ménopausée : diagnostic de confirmation (aménorrhée non médicalement induite depuis au moins 12 mois avant la visite d’inclusion) • Homme avec une partenaire en âge procréer devant prendre une contraception (Cf. CTFG) (oestro-progestatifs ou dispositif intra-utérin ou ligature de trompes) à l’inclusion, pendant la durée de l’étude. |
|
E.4 | Principal exclusion criteria |
- Pregnant woman, parturient, breastfeeding woman, woman able to procreate who has not had effective contraception according to the WHO definition (oestro-progestin or intra-uterine device or tubal ligation) for at least 3 months - Patient deprived of liberty by an administrative or judicial decision or subject of legal age (under guardianship or curatorship) - Exclusive passive fecal incontinence - Person suffering from constipation (Rome IV criteria) -Person presenting an inflammatory or cancerous digestive pathology - History of rectal surgery - Person participating in another research protocol or having participated in another research protocol within 4 weeks prior to the inclusion visit - Patients unable to receive botulinum toxin injections - patients who cannot tolerate short colonoscopy or manometry recording - patients with contraindications to colonic purging
|
- Femme enceinte, parturiente, allaitante, femme en mesure de procréer n’ayant pas de contraception efficace selon la définition de l’OMS (oestro-progestatifs ou dispositif intra-utérin ou ligature de trompes) depuis au moins 3 mois - Patient privé de liberté par une décision administrative ou judiciaire ou sujet majeur protégé (sous tutelle ou curatelle) - Incontinence fécale passive exclusive - Personne souffrant de constipation (critères de Rome IV) -Personne présentant une pathologie digestive inflammatoire ou cancéreuse évolutive - Antécédent de chirurgie rectale - Personne participant à un autre protocole de recherche ou ayant participé à un autre protocole de recherche dans les 4 semaines précédant la visite d’inclusion - patients ne pouvant recevoir les injections de toxine botulique - patients ne pouvant supporter la coloscopie courte ou l’enregistrement par manométrie - patients ayant des contres indications à la purge colique
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint was the time to onset of high amplitude propagative contractions (HAPC) after instillation of DULCOLAX® in the sigmoid and rectum, before and 1 month after intra-rectal botulinum toxin injections. |
Le critère de jugement principal est le délai d’apparition des contractions propagées de grande amplitude (= « high amplitude propagative contractions », HAPC) après instillation de DULCOLAX® au niveau du sigmoïde et du rectum, avant et 1 mois après injections intra-rectales de toxine botulique. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
1 month after BOTOX injection |
1 mois après les injections de BOTOX |
|
E.5.2 | Secondary end point(s) |
The secondary endpoints were: - The characteristics of the contractions at the level of the rectum and the sigmoid measured before then 1 month after injections of botulinum toxin: number, frequency, amplitude, duration of the HAPC, index of contractility, number and characteristics of the contractions (propagated or retropropagated). - Expulsion or not of the probe (which is an indirect sign of the efficiency of the colorectal motricity) as well as the delay of expulsion of the probe. - Severity scores (Cleveland Score, Appendix 2), stool schedule and quality of life score (FIQL Score, Appendix 4) before and 1 month after botulinum toxin injections. - Adverse events, which will be collected at each visit - Tolerance of the botulinum toxin treatment
|
Les critères de jugement secondaires sont : - Les caractéristiques des contractions au niveau du rectum et du sigmoïde mesurés avant puis 1 mois après injections de toxine botulique : nombre, fréquence, amplitude, durée des HAPC, index de contractilité, nombre et caractéristiques des contractions (propagées ou retropropagées). - Expulsion ou non de la sonde (qui est un signe indirect d’efficacité de la motricité colo-rectale) ainsi que le délai d’expulsion de la sonde. - Les scores de sévérité (Score de Cleveland, Annexe 2), le calendrier des selles et le score de qualité de vie (Score FIQL, Annexe 4) avant et 1 mois après injections de toxine botulique. - Les évènements indésirables, qui seront recueillis à chaque visite - La tolérance du traitement par toxine botulique
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1 month after botulinum toxin injections. |
1 mois après injections de toxine botulique. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 4 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 4 |